neuroendocrine carcinoma
Jump to navigation
Jump to search
Pathology
- well-differentiated neuroendocrine carcinomas are indolent[1]
- most express somatostatin receptors[2]
Radiology
- serial imaging with CT or MRI with contrast for well-differentiated neuroendocrine carcinomas[1]
Management
- well-differentiated neuroendocrine carcinomas may be observed[1]
- hepatic artery embolization used to treat localized neuroendocrine carcinomas of the liver[1]
- high-grade neuroendocrine carcinoma of unknown primary should be treated with
- metastatic neuroendocrine tumors may be treated with systemic chemotherapy, or peptide receptor radionuclide therapy*[3]
* a radionuclide linked to a somatostatin analogue targets somatostatin receptor- expressing neuroendocrine tumors
More general terms
More specific terms
- medullary thyroid carcinoma
- Merkel cell carcinoma (neuroendocrine cancer of skin, trabecular cancer)
- small cell carcinoma of the lung (SCLC, oat cell carcinoma)
Additional terms
References
- ↑ Jump up to: 1.0 1.1 1.2 1.3 1.4 1.5 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
- ↑ Jump up to: 2.0 2.1 Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well- differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009 Mar;6(3):143-52. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19190591
- ↑ Jump up to: 3.0 3.1 Kipnis ST, Hung M, Kumar S et al Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open. 2021;4(3):e212274 March 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33755166 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777778